Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

TransCode Therapeutics, Inc. (RNAZ)

0.5885   -0.102 (-14.8%) 09-27 16:00
Open: 0.621 Pre. Close: 0.6907
High: 0.68 Low: 0.574
Volume: 5,015,308 Market Cap: 1(M)

Technical analysis

as of: 2023-09-27 4:21:50 PM
Short-term rate:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Mid-term rate:       
Target: Six months: 2.53     One year: 3.73
Support: Support1: 0.5    Support2: 0.41
Resistance: Resistance1: 2.16    Resistance2: 3.2
Pivot: 0.88
Moving Average: MA(5): 1.03     MA(20): 1.03
MA(100): 2.68     MA(250): 8.05
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 28.7     %D(3): 32.4
RSI: RSI(14): 42.6
52-week: High: 31  Low: 0.5
Average Vol(K): 3-Month: 2,472 (K)  10-Days: 14,453 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ RNAZ ] has closed above bottom band by 34.4%. Bollinger Bands are 41.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.68 - 0.69 0.69 - 0.69
Low: 0.57 - 0.57 0.57 - 0.57
Close: 0.58 - 0.59 0.59 - 0.59

Company Description

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Headline News

Tue, 26 Sep 2023
Why Transcode Therapeutics (RNAZ) Stock Is Down Nearly 70% - TransCode Therapeutics (NASDAQ:RNAZ) - Benzinga

Mon, 25 Sep 2023
TransCode Therapeutics Announces Pricing of $8 Million Public Offering - Yahoo Finance

Mon, 25 Sep 2023
Healthcare Stocks on the Move Monday: RNAZ, VACC, BPTS, CARM, SCYX, MORF, AXLA, APLT - InvestorsObserver

Mon, 25 Sep 2023
The Intriguing Event of a Stock Trading Halt - Best Stocks

Mon, 25 Sep 2023
Trading Halt on NASDAQ Understanding the Reasons and Impact - Best Stocks

Mon, 25 Sep 2023
The Implications and Reasons Behind Trading Halts - Best Stocks

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 2 (M)
Shares Float 2 (M)
% Held by Insiders 29.5 (%)
% Held by Institutions 1.5 (%)
Shares Short 24 (K)
Shares Short P.Month 15 (K)

Stock Financials

EPS -24.73
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.07
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -128
Return on Equity (ttm) -256
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -10.05
Qtrly Earnings Growth 0
Operating Cash Flow -17 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio -0.03
PEG Ratio 0
Price to Book value 0.55
Price to Sales 0
Price to Cash Flow -0.07

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.